Receptor basis for dopaminergic supersensitivity in Parkinson's disease

IN patients with Parkinson's disease, the concentration of dopamine in the basal ganglia of the brain is markedly reduced in accordance with the degeneration of the nigrostriatal dopamine-containing neurones1,2. This fact provided the basis for the successful clinical introduction of L-dopa (L-3,4-dihydroxyphenylalaline) for Parkinson's disease3,6. It has… CONTINUE READING